Aurora Spine Corp. · TSXV:ASG
Aurora Spine — Investor Presentation (2025)
29 slides from Aurora Spine's investor presentation, 2025
Slide 1: Investor Presentation Fall 2025
Investor Presentation TSXV: ASG Fall 2025 OTCQB: ASAPF Aurora Spine, Inc.
Slide 2: Forward Looking Disclaimer
Forward Looking Disclaimer This presentation contains certain statements that may be deemed "forward-looking statements." All statements in this document, other than statements of historical fact, that address events or developments that the Company expects to occur, are forward looking statements.
Slide 3: Company Overview
Company Overview Aurora Spine has developed a portfolio of solutions for the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies, making procedures easier and more effective for doctors and patients. • Headquartered in Carlsbad, CA • Emp
Slide 4: Mission & Philosophy
Mission & Philosophy Innovation targeted at each patient’s well-being Aurora began with a vision to develop high-quality, less invasive implants that prioritize the patient's health. Our philosophy is to make our implants match the patient's anatomy, not to make their anatomy fit our implants. Today
Slide 5: Recent Accomplishments
Recent Accomplishments • SiLO Franchise Gaining Sales Momentum: Sales of the • Record Revenues: Company reported SiLO-TFX SI joint implant increased 135% in 2024, due to record revenues for four consecutive investments in surgeon education, expansion of quarters and annually, with FY24 being instrum
Slide 6: Back Pain Market And Patient Options
Back Pain Market And Patient Options Back Pain Market Treatment Intensity 30M+ in the U.S. suffer from lower back pain 13M+ go to the Non-Surgical Minimally Invasive Open Spine doctor each year for Management Surgery Surgery chronic back pain • Medications • Therapeutics • SI Joint Fusion • Cervical
Slide 7: Emerging Market – Pain Management
Emerging Market – Pain Management The global pain management devices market size is expected to reach USD $14.55 billion by 2026 Number of Pain registering a CAGR of 13.8%. Interventionalists vs. Aurora entered market in November 2020 Spine Surgeons • Introduced two key products for the pain market:
Slide 8: Growth Initiatives
Growth Initiatives Internal Sales & Marketing 1 CEO, 1 CCO & 1 VP of Sales 6 Regional Sales Directors 3 Territory Managers ~50 active distributors Aurora's Quality Management System is ISO 13485 MDSAP certified that allows the company to sell its products in Japan, Australia, Brazil, Canada and the
Slide 9: Key Value Creation Driver: Proprietary Products
KEY VALUE CREATION DRIVER: Proprietary Products Aurora Spine, Inc.
Slide 10: Proprietary Product Platforms
Proprietary Product Platforms Aurora Spine currently has several Hydra proprietary product platforms, created to add significant value to the company. Launched 2024 Patented Technology FDA 510K Cleared. Scoli/Deformity DEXA-C Launched 2023 Patented Technology FDA 510K Cleared. Cervical & Lumbar DEXA
Slide 11: Proprietary Product: zip Series
Proprietary Product: zip Series The zip is Aurora Spine’s minimally invasive interspinous fixation implant for spinal fusion (screwless procedure). It was developed as an alternative to pedicle screw fixation. • Over 10,000 procedures performed to date • Reduces OR time by 36%: 98 minutes vs. 153 mi
Slide 12: Proprietary Product: SiLO
Proprietary Product: SiLO SiLO Posterior Si Joint Fusion System • Addresses new market opportunity for Aurora Spine -- Joint Pain • Sacroiliac joint (Si Joint) fusion is a surgical procedure which fuses the iliac bone (pelvis) to the spine (sacrum) for stabilization. • The Global MIS Sacroiliac Join
Slide 13: Proprietary Product: SiLO TFX
Proprietary Product: SiLO TFX SiLO TFX is Aurora Spine's MIS Transfixing Si Joint Fusion System. • A Crossover product: Ortho, Neuro, and Pain Physicians can all use this product. • Commercially Launched: Q2:23 • Fastest growing product for Aurora SiLO Revenue by Quarter $3 $2.6 $3 $2.3 $2.3 $USD in
Slide 14: Proprietary Product: DEXA Technology & apollo
Proprietary Product: DEXA Technology & apollo • The apollo is part of the DEXA Technology family of products. • The system is comprised of cervical plates and bone screws constructed of titanium alloy. • A wide array of implant length options to match a variety of patient anatomies and to facilitate
Slide 15: Proprietary Product: DEXA-C
Proprietary Product: DEXA-C Having low bone density or osteoporosis affects 54 million Americans. The DEXA-C Cervical Interbody Cage can match the bone density of the patient, promote bone growth, and provide better implantation. • Implant stiffness correlates to Bone Quality • Acts and looks like b
Slide 16: Proprietary Product: DEXA-L
Proprietary Product: DEXA-L A Lumbar Interbody Fusion System The DEXA-L Stand-Alone ALIF System can match the bone density of the patient, promote bone growth, and provide better implantation. • Implant stiffness correlates to Bone Quality • Acts and looks like bone • DEXA-L tunes its stiffness to m
Slide 17: Proprietary Product: HYDRA
Proprietary Product: HYDRA Pioneering Roughened Surface Technology in Spinal Screw Systems • Pioneering roughened surface technology • Complex spine, and minimally invasive spine procedures • Elevate stability, micromotion, and loosening Aurora Spine, Inc. 17
Slide 18: Proprietary Product: HYDRA A.E.R.O. Facet Fusion System
Proprietary Product: HYDRA A.E.R.O. Facet Fusion System • FDA 510(k) cleared March 2025 • Novel device designed to provide minimally invasive solution for patients suffering from facet joint-related pain or instability • Cleared for spinal levels C2 to S1 (inclusive) • Can be used in Lumbar and Cerv
Slide 19: Financials
FINANCIALS Aurora Spine, Inc.
Slide 20: Income Statement Highlights – Annual
Income Statement Highlights – Annual Revenue Gross Profit Margins Adjusted EBITDA $18 $17.6 70% $0 $0.3 60.5% $0 $16 60% 56.5% $14.8 52.5% $0 $14.3 $14 50% 45.8% ($0) $USD in Millions 40.1% ($0) ($0.3) ($0.3) $12 $11.2 40% $ in USD $10.5 31.8% ($1) ($0.5) $10 30% ($0.6) $8.6 ($1) $8 20% ($1) ($1) $6
Slide 21: Income Statement Highlights - Quarterly
Income Statement Highlights - Quarterly Revenue Gross Profit Margins Adjusted EBITDAC $5 65% $1 $4.8 $4.7 62.4% $0.4 61.9% 62.2% $0 $5 $4.4 $4.5 59.7% 60.5% 58.0% $0 60% $4.0 $4.1 57.8% $3.9 $3.9 56.9% 56.7% $0 $0.1 $4 $0.1 $0.1 $0.1 $0.1 $USD in Millions $3.6 $0 55% $ in USD $4 51.7% $0 $3.0 ($0) (
Slide 22: Balance Sheet Highlights
Balance Sheet Highlights $ in USD 6/30/2025 3/31/2025 12/31/2024 Cash and cash equivalents $580,978 $488,693 $825,621 Accounts receivable, net $4,089,212 $4,098,086 $3,784,858 Inventory $3,831,694 $3,817,659 $3,613,557 Total current assets $8,694,620 $8,633,882 $8,500,120 Property, plant and equipme
Slide 23: Capitalization Summary
Capitalization Summary Stock Details Key Shareholders Stock price: $0.21 25.2% - All Insiders (Board of Directors and 52-week range: $0.17-$0.34 Management) Shares outstanding: 78.1 million 16.1% - David Rosenkrantz, Chairman Market capitalization: $16.4 million 6.9% - Trent Northcutt, CEO 2.2% - Ot
Slide 24: Milestones And Objectives
Milestones And Objectives Proprietary product platforms to drive revenue growth and profitability • ZIPTM Interspinous Fixation Device – screwless procedure • SiLO-TFXTM – novel solution for SI Joint pain; growing rapidly in expanding market • DEXATM products: DEXA-C and DEXA-L; Apollo cervical plat
Slide 25: Appendix
APPENDIX Aurora Spine, Inc.
Slide 26: Management Team
Management Team Trent Northcutt Laszlo Garamszegi Dave Meyer Chad Clouse Matthew Goldstone Chief Executive Officer Chief Technology Officer VP & Chief Legal Officer Chief Financial Officer Chief Commercial • 20+ years experience in Officer • 20+ years experience in • 25+ years of legal medical devic
Slide 27: Board Of Directors
Board Of Directors David Rosenkrantz Trent Northcutt Mike Seid Daryl Maclellan Tracy Graf Chairman CEO Board Member Board Member Board Member • 18+ years • 20+ years experience in • 17+ years of • President of Desante • President of Carfinco experience in medical device market investment, finance, F
Slide 28: Strong Patent Portfolio
Strong Patent Portfolio Title Ser. or Pat. No Filing Date Issue Date Continuity Data Status Dynamic and Non-Dynamic Interspinous Fusion Implant Granted 9,364,267 4-17-13 6-14-16 and Bone Growth Stimulation 7.5 Year MF Open 6-14-23 Aurora Spine’s Intellectual System Property Dynamic and Non-Dynamic I
Slide 29: Spine Surgery Market Overview
Spine Surgery Market Overview • Majority of spine surgery is targeted at relieving pain caused by disc injury or disease • Most surgeries involve damaged disc remediation or removal • Removal necessitates fusing together of the vertebrae above and below the damaged area • Vertebrae must be held in p